-
Another new drug withdrew its drug registration application!
Time of Update: 2022-08-15
Buchang Pharmaceutical announced on the evening of May 9 that due to the need to further improve the application materials for fasudil hydrochloride injection, after careful research and decision, Tonghua Guhong applied to the State Food and Drug Administration to withdraw the drug registration of fasudil hydrochloride injection apply .
-
The world's first FcRn antagonist is about to be launched in China, bringing new hope to 200,000 patients
Time of Update: 2022-08-15
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
-
Enthusiasm for the research and development of oncology drugs is high. This pharmaceutical company has 9 new class 1 tumor drugs approved for clinical use during the year.
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] According to CDE's public information, Hengrui Medicine's HRS-4642 injection has recently been approved for clinical use in KRAS G12D-mutated advanced solid tumors .
-
In 2021, the total number of new drug clinical trial registrations in China exceeded 3,000 for the first time, and the research and development of PD-1/PD-L1 is particularly outstanding!
Time of Update: 2022-08-15
The "Report" shows that according to the classification of chemical drugs, biological products and traditional Chinese medicines, from the data analysis of the past three years, the proportion of new drug clinical trials of chemical drugs and biological products is relatively high, with an annual average of 54.
-
More than 10 pharmaceutical companies announced their "transcripts" in the first half of the year, and many net profits doubled
Time of Update: 2022-08-15
. In the first half of 2022, the company achieved revenue of 642 million yuan, a year-on-year increase of 41.
97%, and profitability accelerated In the first half of 2022, the company achieved revenue of 642 million yuan, a year-on-year increase of 41.
-
The B certificate application process is optimized, and the trustee GMP certificate is exempted!
Time of Update: 2022-08-15
The flow of approval documents between provinces has been ignited at the policy level . Since mid-May, four provinces of Anhui, Sichuan, Hebei and Shanxi have issued relevant policies that are conduc
-
AI pharma trend sweeps to create a "new normal" for drug research and development
Time of Update: 2022-08-15
The current AI pharmaceutical projects under research are widely distributed in cancer, respiratory system, anti-infection, mental disorders, immune system, ophthalmology, cardiovascular, digestive s
-
Deconstructing the Six Variables of Normalized Medical Reform
Time of Update: 2022-08-15
The state takes the establishment of a normalized and institutionalized centralized procurement mechanism, the establishment and improvement of a long-term mechanism for fund supervision, the establishment and improvement of treatment guarantee policies, deepening the reform of medical service prices, deepening the reform of medical insurance payment methods, and carrying out medical insurance drug catalog negotiations and standardized management as reforms.
-
The use of essential medicines has been upgraded!
Time of Update: 2022-08-15
What has attracted much attention from the industry is that the new version of the "Operation Manual" further clarifies that the number of varieties of essential drugs purchased and the proportion of their use are included in the assessment points of secondary public hospitals .
-
The battle for the "Drug King" is full of thrills and dangers. Can K medicine reach the top? Can ADC become the next legend?
Time of Update: 2022-08-15
Drug K is an anti-tumor drug developed and produced by Merck & Co. As a PD-1 antibody product that has been the focus of academia and industry for a long time, its every move has attracted industry attention from research and development, clinical to marketing, and the continuous expansion of indications.
-
The 2021 drug review report is released!
Time of Update: 2022-08-15
The "Report" shows that in 2021, the Drug Evaluation Center of the State Drug Administration will accept 11,658 registration applications, a year-on-year increase of 13.
The "Report" shows that in 2021, the Drug Evaluation Center of the State Drug Administration will accept 11,658 registration applications, a year-on-year increase of 13.
-
Question is high!
Time of Update: 2022-08-15
If you don’t catch up with the live broadcast, move your small bench to find the answer in the review~ Then, Zhuang Kai takes us to the second perspective of sludge treatment and disposal - ""No Urban Solid Waste Treatment and Disposal under the Background of “Waste City” Construction: Experience in Deep Water How does the "gas, liquid and slag" technical route of Bei Pai deal with these problems?
-
Hengrui's 10 new drugs were approved, refreshing market investment expectations!
Time of Update: 2022-08-15
?Since the beginning of this year, the capital market has reassessed the value of China's pharmaceutical innovation, and the stock prices of a large number of pharmaceutical innovation companies represented by Hengrui Medicine have fallen .
-
On June 15, the fifth round of interpretation of the new standard of drinking water GB5749 will meet again!
Time of Update: 2022-08-15
Therefore, it is necessary to 2 -Methyl isocamphenol, geosmin and other substances are detected Among them, there are many problems of exceeding the standard of organic matter and microorganism detection, and this new standard focuses on chroma, turbidity, odor and taste, which are closely related to the direct impact of algae outbreaks on water quality in recent years.
-
With the continuous improvement of innovation capabilities of local pharmaceutical companies, they are accelerating their internationalization strategies
Time of Update: 2022-08-15
Recently, it was reported that the international multi-center phase III clinical trial of 2 innovative drugs of Hengrui Medicine of camrelizumab for injection (Erica®) combined with apatinib mesylate tablets (Aitan®) (SHR-1210-III-310) The independent data monitoring committee (IDMC) judged that the primary endpoint of the study met the protocol-preset superiority standard .
-
12 models were approved in the first half of the year!
Time of Update: 2022-08-15
【Pharmaceutical Industry News】 In recent years, with the strong support of the state, the development of children's medicine has shown a steady trend . According to statistics, among the new drugs ap
-
The semi-annual reports of biopharmaceutical companies have been released one after another. Innovent, Henlius, Betta, etc. have entered the CDMO market strongly! Is it better to "sell water" to be innovative drugs?
Time of Update: 2022-08-15
In fact, in addition to the old CDMO players, Biotech innovative pharmaceutical companies as Party A have recently entered the CDMO Party B market, which has attracted industry attention: In May of this year, Innovent Bio launched Sherpa Bio. In addition to the production and supply of Innovent Bio’s current biopharmaceutical pipeline, Sherpa Bio will also undertake CDMO business as a means to improve the company’s efficiency .
-
The county-level drug market will expand again, and pharmaceutical companies will usher in a new round of development opportunities
Time of Update: 2022-08-15
For example, in November last year, the National Health and Medical Commission issued the "Thousand-County Project" County Hospital Comprehensive Capacity Improvement Work Plan (2021-2025), which determined that by 2025 at least 1,000 county-level medical institutions across the country will reach Level 3.
-
GSK's single-tablet, dual-drug HIV drug Dovito® approved for expanded indications
Time of Update: 2022-08-15
Agency approval as a complete regimen for the treatment of HIV-1-infected adults and adolescents over 12 years of age who have achieved virological suppression On May 11, GlaxoSmithKline (GSK) announced that its innovative single-tablet dual-drug HIV treatment program, Dovito (generic name: lamivudine and dolutegravir), has been officially approved by the National Medical Products Administration of China for its expanded indications.
-
The research and development hotspots of innovative therapeutics and pharmaceutical companies, these areas have become the focus of attention
Time of Update: 2022-08-15
For example, on the 17th, Travere Therapeutics announced that the US FDA has granted the company priority review status for the new drug application submitted by the company for the investigational therapy sparsentan for the treatment of IgA nephropathy .
